Kerecis, based in Iceland with a U.S. subsidiary, developed a revolutionary technology using fish skin to repair damaged human tissue, including severe and chronic wounds. Kerecis discovered a way to transform fish skin so that it retains its natural three-dimensional structure and the naturally occurring omega-3 fatty acids while sterilizing and drying the skin so that it can be used in a scale-free form for direct placement on a wound.  FDA-approved and sourced from freshly caught fish from the cold North Atlantic Ocean, the unique fish-skin product called Kerecis Omega3 is inserted into damaged human tissue, where it is vascularized and populated by the patient’s own cells and ultimately converted into living tissue.

This product has been approved as a medical device in multiple jurisdictions (including the U.S. and Europe) for indications such as burns and diabetic wounds. In addition, the Kerecis Omega3 fish skin technology is being developed for use in products to treat oral soft tissue defects, dura matter repair, breast reconstruction, and abdominal wall reconstruction as well as for surgical stapling and reinforcement. Kerecis is also participating in several U.S. Department of Defense funded research projects aimed at developing better remedies for injured American service members.

Medical providers using Kerecis Omega3 have reported outstanding results in the treatment of chronic wounds such as those caused by diabetes and other ailments that up to now were very difficult to treat using alternate solutions.

The attorneys at Workman Nydegger, with advanced degrees in biotechnology and hands-on industry experience, have been instrumental in securing patents and other intellectual property rights for Kerecis in the U.S. and other countries since it was established in 2009. We are proud to continue to represent this Icelandic based company as it strives toward its goal of becoming an international medical device supplier.